In this episode, Vic and Marcus cover a sweeping range of major developments in healthcare, policy, and the economy. They dive deep into the UnitedHealth Group crisis, discussing the CEO resignation, DOJ investigation, and stock collapse. They analyze inflation data, Microsoft layoffs, and U.S.-China trade pauses, while also breaking down emerging trends in biotech, AI-driven drug development, hospital discharge tech, and venture capital movement. The hosts explore RFK Jr.'s impact on CMS policy, Medicaid cuts, Roundup controversies, IPO market challenges, and gene-editing breakthroughs—all framed by their signature lens on innovation, impact, and policy shifts.

Links:

6:13 - Surprise U.S.-China Trade Deal Gives Global Economy Reprieve WSJ

9:07 - Mild April Inflation Captures Early Stages of Tariff Effects WSJ

9:57 - Microsoft Slashing Thousands of Workers, Including Management Jobs WSJ

11:16 - Clarium lands $27M to fortify hospital supply chains Axios

12:09 - Olio Secures $11M to Scale Care Coordination Platform HIT

13:30 - J&J, Eli Lilly join $85M financing for newly unveiled gene editing biotech Stylus Fierce Healthcare

15:19 - Somite, a developer of foundation models for the human cell, raised $47m in Series A. X

16:35 - Cohere Health lands $90M series C round to expand AI use cases Fierce Healthcare

17:24 - Pathos AI raises $365M at $1.6B valuation Axios

18:21 - State of Private Markets: Q1 2025 Carta

23:07 - CMS proposes crackdown on 'money laundering' provider tax policies Modern Healthcare

24:25 - Drugmakers Avoid Worst-Case Pricing Scenario for Now WSJ

25:14 - Trump Leadership: If You Want Welfare and Can Work, You Must NYT-Op

28:15 - $715B Medicaid cut passes House committee in reconciliation bill Healthcare Finance

30:23 - Trump Officials Balk at RFK Jr.’s Attack on Pesticides WSJ

31:17 - CMS Innovation Center Strategy to Make America Healthy Again CMS website

36:48 - UnitedHealth CEO Is Out, Sending Shares Plummeting WSJ

40:08 - UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud WSJ

51:25 - Kaiser Permanente sees 16.1% year-over-year Q1 revenue growth following Risant acquisitions Fierce Healthcare

51:46 - Omada Health Files to Go Public: Will It Be Successful? MedCity

53:06 - Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy WSJ

53:44 - Bayer Shares Jump After Results Beat Expectations on Pharma Strength WSJ

54:10 - GSK Makes a Big Liver Disease Move With $1.2B Deal for Phase 3-Ready MASH Drug 54:10 - MedCity News

54:57 -

HF Site

YOUTUBE
INSTAGRAM
TWITTER
FACEBOOK
LINKEDIN
TIKTOK